

The conjunctiva as a site for investigation of human mucosal immunology *in situ* – elucidating the mechanisms of immune escape in adenovirus-induced epidemic keratoconjunctivitis (EKC)

Makoto Yawata^{1,2}, Kevin John Selva², Jay Siak³, Liu Yu Chi³, Louis Tong^{3,4}, Jodbhir S. Mehta^{3,4}, Nobuyo Yawata^{2,3,4}

¹Department of Pediatrics, School of Medicine, National University of Singapore

²Singapore Institute for Clinical Sciences, Agency for Science Technology and Research

³Singapore Eye Research Institute

⁴Duke-NUS Graduate Medical School

Topics


**Inflammation of the ocular mucosal surface caused by adenovirus infection
– EKC (epidemic keratoconjunctivitis)**

Human NK cell populations and their regulation


Profiling NK cells in the conjunctiva mucosa over the course of EKC

Elucidating the mechanisms of immune subversion by adenoviruses

Group D human adenoviruses (HAdV) cause epidemic keratoconjunctivitis (EKC)



Severe conjunctivitis



Subepithelial keratitis



Pseudomembrane


Human adenovirus types are classified into seven groups

Group	Type	Clinical diseases
A	12, 18, 31	
B	3, 7, 11, 14...	Conjunctivitis Pharyngitis Pneumonia
C	1, 2, 5, 6	Pharyngitis Pneumonia
D	8, 9, 19, 37, 53, 54...	EKC
E	4	Conjunctivitis Pneumonia
F	40, 41	Gastroenteritis
G	52	Gastroenteritis


Clinical features of epidemic keratoconjunctivitis (EKC)

Severe and prolonged inflammation
Group D Human adenoviruses (HAdV) cause EKC

Severe conjunctivitis




Pseudomembrane




- Conjunctivitis (non EKC)
- Conjunctivitis (EKC)

Natural Killer cells provide initial protection against virus infections and prime adaptive immunity



NK cells are controlled through a balance in signaling from inhibitory and activating factors



Cell contact factors	Killer Cell Immunoglobulin-like Receptors (KIR2DL1/2/3, 3DL1)	2DS1, 3DS1
	<u>NKG2A</u>	<u>NKG2C</u>
	LILRB1	<u>NKG2D</u>
		<u>DNAM-1</u>
		NKp30/46
		CD16

Soluble factors

**IL-10
TGF- β**

**IL-12, IL-15, IL-18
IFN- α
IL-2**

HLA class I-specific inhibitory receptors create NK cell heterogeneity


Inhibitory receptors

	<i>Receptor</i>	<i>Ligand</i>
Variable	KIR2DL1	HLA-C2
	KIR2DL2/3	HLA-C1
	KIR3DL1	HLA-B Bw4
	KIR2DL4	HLA-G
	KIR2DL5A,5B	?
	KIR3DL2	HLA-A3/11
	KIR3DL3	?
Conserved	NKG2A/CD94	HLA-E
	LILRB1 LILRB2	HLA-A,B,C,G


Activating receptors

<i>Receptor</i>	<i>Ligand</i>
KIR2DS1,2,3,4,5	HLA-C?
KIR3DS1	?
KIR2DL4	HLA-G
NKG2C	HLA-E
NKG2D	MICA&B/ULBP
CD16	Fcγ
CD160	HLA-C
2B4	CD48
NKp30	BAT3
NKp44	HA
NKp46	HA
DNAM-1	CD112/155

Variegated expression




Homogeneous expression




Yawata et al. Blood 2009

'Missing-self' response is unique to NK cells




Normal cells

Reduced inhibition of NK cells through cognate KIR-HLA class I interaction




Abnormal cells
virally infected cells
cancer cells

Human natural killer cell subsets have distinct function






	Mature	Immature
Cytotoxicity	+++	+
Cytokine production by monokines	+	+++
Chemokine receptors	CXCR1, CX3CR1	CXCR3, CCR5, CCR7
HLA specific inhibitory receptors	KIR, NKG2A	NKG2A
ADCC	CD16⁺⁺	CD16⁻

NK cell populations in human organs




Mature CD56^{dim} NK cells are the dominant type in the conjunctiva




Yawata et al., Mucosal Immunology 2015


Ocular surface NK cells produce anti-viral cytokines, similar to those in peripheral blood



CD56^{bright} NK cells increase in acute adenovirus-induced conjunctivitis




CD56^{bright} NK cells increase in adenovirus-induced conjunctivitis




Elevated levels of chemokines that recruit CD56^{bright} NK cells are identified in the tear fluid in the acute phase of adenovirus-infected conjunctiva

Chemokines attracting CD56^{bright} NK cells (CXCR3, CCR5)



Chemokines attracting CD56^{dim} NK cells (CXCR1, CXCR2, CXCR4)





- Acute phase
- Convalescent phase
- Healthy control




n=13 Multiplex beads assay

Yawata et al., Mucosal Immunology 2015

The CD56^{bright}, immature NK cells express the receptors CXCR3 and CCR5 in the acute phase of viral inflammation





The conjunctiva NK cells recruited to the conjunctiva in adenovirus infection (CD56^{bright} NK cells and NKG2A⁺NK cells) display are functionally suppressed





Summary from *ex vivo* study

1. Mature NK cells are the dominant NK cell type in the conjunctiva.
2. Immature NK cells are recruited during adenovirus infection.
3. NKG2A⁺NK cells increase in severe conjunctival inflammation.
4. Mature NKG2A⁻NK cells display an activated state.

CD56^{dim} NK cells produce IFN-g against HAdV-infection




Cell contact-dependent NK cell activation in HAdV infection




Inhibitory receptor–ligand interactions?
Activating receptor–ligand interactions?


Weaker IFN- γ production by NKG2A⁺NK cells




NKG2A⁺ NK cells showed lower response against HAdV-infected cells




Weaker IFN-g production by NKG2A+NK cells



Lower IFN- γ response by NK cells against group D HAdVs




DNAM-1 and NKG2D are key for NK cell activation against HAdV infection




n=3

Ligands for DNAM-1 are reduced in HAdV-8 infection




Group D HAdVs down-regulate specific activating ligands on infected epithelia and dampen NK cell responses



Summary

- ❑ Immature CD56^{bright}NK cells and NKG2A⁺mature CD56^{dim}NK cells are inhibited by **up-regulated inhibitory ligand** on HAdV-infected epithelium.
- ❑ Group D HAdV escape from mature NK cell anti-viral response by **down-regulating activating ligands** on infected cells.



Acknowledgements

Singapore Eye Research Institute (SERI)

Woon Kaing
Jessie Lim
Kevin John Selva
Yu-Chi Liu
Jodhbir Singh Mehta
Louis Tong
Wanwen Lan

Singapore National Eye Centre (SNEC)

Jay Jyh Kuen Siak
Anshu Arundhati

Singapore Institute for Clinical Sciences (SICS)

Nobuyo Yawata

National University of Singapore (NUS)

Naoki Yamamoto

Hokkaido University

Koki Aoki
Hidemi Watanabe
Shigeaki Ohno

Fukushima Medical University

Hisatoshi Kaneko

National institute of Infectious diseases

Tsuguto Fujimoto

**Agency for Science, Technology and Research (A*STAR)
National Medical Research Council (NMRC), Singapore**



